Bibliography
- GUO T, HOBBS DW: Development of BACE1 inhibitors for Alzheimer's disease. Curr. Med. Chem. (2006) 13:1811-1829.
- CUMMING JN, ISERLOH U, KENNEDY ME: Design and development of BACE-1 inhibitors. Curr. Opin. Drug Disc. Dev. (2004) 7(4):536-556.
- DURHAM TB, SHEPHERD TA: Progress toward the discovery and development of efficacious BACE inhibitors. Curr. Opin. Drug Disc. Dev. (2006) 9(6):776-791.
- HUSSAIN I, HAWKINS J, HARRISON D et al.: Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. J. Neurochem. (2007) 100:802-809.
- MANAS ES: Structure-based design of Acylguanidine BACE1 inhibitors. Oral Presentation COMP-089 at American Chemical Society 230th National Meeting, Washington, DC, USA (Aug. 28-Sept. 1, 2005).
- COLE DC, MANAS ES, STOCK JR et al.: Acylguanidines as small-molecule β-secretase inhibitors. J. Med. Chem. (2006) 49:6158-6161.
Patents
- MERCK: WO2005018545 (2005).
- ELAN: WO2003006423 (2003).
- GLAXOSMITHKLINE: WO2005113525 (2005).
- BOEHRINGER INGELHEIM: WO2006050861 (2006).
- LILLY: WO2006034093 (2006).
- BRISTOLMYERSSQUIBB: WO2004013098 (2004).
- WYETH: US20060173049 (2006).
- WYETH: WO2006083760 (2006).
- WYETH: US20050282825 (2005).
- WYETH: WO2006088694 (2006).
- WYETH: WO2006088705 (2006).
- WYETH: WO2006088711 (2006).
- WYETH: US20050282826 (2005).
- WYETH: US20070072925 (2007).
- WYETH: US20070027199 (2007).
- WYETH: US20070004786 (2007).
- WYETH: US20070004730 (2007).
- SCHERING/PHARMACOPEIA: WO2005058311 (2005).
- MalamasMSErdeiJJGunawanISNowakPHarrisonLBWyeth corp. et al.Amino-imidazolones for the inhibition of b-secretase. Priority date: 14/01/2005. Filing date: 09/01/2006.WO200607628420072006